Method and system for wound care

Information

  • Patent Grant
  • 9669233
  • Patent Number
    9,669,233
  • Date Filed
    Monday, November 10, 2014
    10 years ago
  • Date Issued
    Tuesday, June 6, 2017
    7 years ago
Abstract
In one aspect, the present invention relates to a wound-care assembly The wound-care assembly includes a base layer. A film layer is operatively coupled to the base layer and a fluid conductor is in fluid communication with a wound and a vacuum source. The wound-care assembly further includes a fiber-optic patch comprising a plurality of fiber-optic strands. The fiber-optic strands are pressed into contact with an interior surface of the wound by the fluid conductor. The fiber-optic patch provides ultraviolet light to the wound and the relative vacuum is applied to the wound via the vacuum source and the fluid conductor.
Description
BACKGROUND

Field of the Invention


The present invention relates to a wound care method and system with one or both of vacuum-light therapy, pulsed radio frequency (“RF”), and oxygenation, and more particularly, but not by way of limitation, to adaptive wound-care patch capable of being utilized in a variety of wound locations where one or both of vacuum-light therapy, pulsed radio frequency (“RF”), and oxygenation may be applied thereto.


History of the Related Art


An important aspect of patient treatment is wound care. Medical facilities are constantly in need of advanced technology for the cleaning and treatment of skin wounds. The larger the skin wound, the more serious the issues are of wound closure and infection prevention. The rapidity of the migration over the wound of epithelial and subcutaneous tissue adjacent the wound is thus critical. Devices have been developed and/or technically described which address certain aspects of such wound healing. For example, U.S. Pat. No. 6,695,823 to Lina et al. (“Lina”) describes a wound therapy device that facilitates wound closure. A vacuum pump is taught for collecting fluids from the wound. WO 93/09727 discloses a solution for wound drainage by utilizing negative pressure over the wound to promote the above references migration of epithelial and subcutaneous tissue over the wound.


In other embodiments, wound treatment is performed using light therapy. For example, U.S. Pat. No. 7,081,128 to Hart et al. (“Hart”) describes a method of treating various medical conditions such as, for example, joint inflammation, edema, etc., utilizing an array of Light Emitting Diodes contained on a flexible substrate that may be wrapped around an anatomical feature of the human body. U.S. Pat. No. 6,596,016 to Vreman et al. (“Vreman”) discloses a phototherapy garment for an infant having a flexible backing material, a transparent liner, and a flexible printed circuit sheet containing surface-mounted LEDs. The LEDs preferably emit high-intensity blue light, suitable for the treatment of neonatal hyperbilirubinemia. The device may include a portable power supply.


In other embodiments, wound treatment is performed using oxygen. The use of oxygen for the treatment of skin wounds has been determined to be very beneficial in certain medical instances. The advantages are multitudinous and include rapidity in healing. For this reason, systems have been designed for supplying high concentration of oxygen to wound sites to facilitate the healing process. For example, U.S. Pat. No. 5,578,022 to Scherson et al. (“Scherson”) teaches an oxygen producing bandage and method. One of the benefits cited in Scherson is the ability to modulate a supply of concentrated hyperbaric oxygen to skin wounds. Although oxygen is beneficial in direct application of predetermined dosages to skin wounds, too much oxygen can be problematic. Oxygen applied to a wound site can induce the growth of blood vessels for stimulating the growth of new skin. Too much oxygen, however, can lead to toxic effects and the cessation of healing of the wound. It would be an advantage, therefore, to maximize the effectiveness of oxygen applied to a wound area by enhancing the absorption rate of oxygen into the skin and tissue fluids. By enhancing the absorption rate of the oxygen in the wound, less exposure time and concomitantly fewer toxic side effects to the endothelial cells surrounding the wound, such as devasculation, occurs. It would be a further advantage, therefore, to utilize existing medical treatment modalities directed toward other aspects of patient therapy to augment oxygenation for wound care.


SUMMARY

The present invention relates generally to a wound care method and system with one or both of vacuum-light therapy, pulsed radio frequency (“RF”), and oxygenation, and more particularly, but not by way of limitation, to adaptive wound-care patch capable of being utilized in a variety of wound locations where one or both of vacuum-light therapy, pulsed radio frequency (“RF”), and oxygenation may be applied thereto.


In one aspect, the present invention relates to a wound-care assembly The wound-care assembly includes a base layer. A film layer is operatively coupled to the base layer and a fluid conductor is in fluid communication with a wound and a vacuum source. The wound-care assembly further includes a fiber-optic patch comprising a plurality of fiber-optic strands. The fiber-optic strands are pressed into contact with an interior surface of the wound by the fluid conductor. The fiber-optic patch provides ultraviolet light to the wound and the relative vacuum is applied to the wound via the vacuum source and the fluid conductor.


In another aspect, the present invention relates to a method of utilizing a wound-care assembly. The method includes applying a fiber-optic patch to a wound. The fiber-optic patch is pressed into contact with an inner surface of the wound via a fluid conductor. The fluid conductor and the fiber-optic patch are secured to the wound. A vacuum applicator is applied to and secured to the fluid conductor. Ultraviolet light is applied to the wound via the fiber-optic patch and a relative vacuum is applied to the wound via the fluid conductor.





BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present invention and for further objects and advantages thereof, reference may now be had to the following description taken in conjunction with the accompanying drawings in which:



FIG. 1A is a top view of a wound-care patch according to an exemplary embodiment;



FIG. 1B is an exploded view of the wound-care patch of FIG. 1A according to an exemplary embodiment;



FIG. 1C is a perspective view of the wound-care patch of FIG. 1A according to an exemplary embodiment;



FIG. 2 is a bottom view of the wound-care patch of FIG. 1 according to an exemplary embodiment;



FIG. 3 is a flow diagram of a method for using the wound-care patch of FIG. 1 according to an exemplary embodiment;



FIG. 4A is a top view of a package containing a wound-care assembly according to an exemplary embodiment;



FIG. 4B is a an exploded view of the wound-care assembly of FIG. 4A;



FIG. 5A is a bottom view of the wound-care assembly of FIG. 4 applied to a foot according to an exemplary embodiment;



FIG. 5B is a top view of the wound-care assembly of FIG. 4 applied to a foot according to an exemplary embodiment; and



FIG. 6 is a flow diagram of a method for using the wound-care patch of FIG. 4 according to an exemplary embodiment.





DETAILED DESCRIPTION

Various embodiments of the present invention will now be described more fully with reference to the accompanying drawings. The invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.



FIG. 1 is a top view of a wound-care patch 100. The wound-care patch 100 includes a base layer 102 that is coupled to a film layer 104. In a typical embodiment, the base layer 102 is constructed of a sterile, ethylyne-oxide, biocompatible material. The film layer 104 is, in a typical embodiment, constructed from, for example, medical grade polyurethane. A peripheral edge 106 of the film layer 104 is secured to a corresponding edge of the base layer 102 through a process such as, for example, welding. Connection of the film layer 104 to the base layer 102 creates a seal around the peripheral edge 106, which seal prevents leakage of fluid therefrom. A fluid port 114 is formed in the film layer 104.


Still referring to FIG. 1, a fluid conductor 108 is disposed between the base layer 102 and the film layer 104. In a typical embodiment, the fluid conductor 108 is flexible, absorptive, and constructed of, for example, medical grade foam. The fluid conductor includes a wound-treatment portion 110 disposed proximate a wound (not shown in FIG. 1) and a straw portion 112 that fluidly couples the wound-treatment portion 110 to the fluid port 114. In a typical embodiment, the fluid conductor 108 transmits fluids such as, for example, liquids or gases, from the wound to the fluid port 114 and, thus, allows a vacuum to be applied to the wound via the fluid port 114. In addition, the straw portion 112 facilitates placement of the fluid port 114 at a location removed from the wound. Such an arrangement is beneficial if, for example, space constraints do not allow the fluid port 114 to be placed near the wound.


Still referring to FIG. 1, a fiber-optic cable 116 is coupled to the wound-care patch 100. A plurality of fiber-optic strands 118 extend from the fiber-optic cable 116. The fiber-optic strands are disposed between the base layer 102 and the film layer 104 and are arranged in a generally flat, side-by-side configuration. The fiber-optic strands 118 are disposed beneath the fluid conductor 108.



FIG. 1B is an exploded view of the wound-care patch 100. FIG. 1C is a perspective view of the wound-care patch 100. FIG. 2 is a bottom view of the wound-care patch 100. Referring to FIGS. 1B-2 together, a window 120 is formed in a bottom face of the base layer 102. The fiber-optic strands 118 extend across the window 120. The wound-treatment portion 110 of the fluid conductor 108 (shown in FIG. 1A) is disposed over the window 120 above the fiber-optic strands 118. In a typical embodiment, the wound-care patch 100 is arranged such that the window 120 is positioned over the wound. A mesh 121 extends across the window 120 below the fiber-optic strands 118. In a typical embodiment, the mesh 121 prevents adhesion of wound tissue to either the fiber-optic strands 118 or the fluid conductor 108. A biocompatible skin adhesive (not shown) such as, for example, Tegaderm™, manufactured by 3M Company (hereinafter “Tegaderm”), is used to secure the edges of the wound-care patch 100 to skin surrounding the wound.


During operation, a vacuum pump (not explicitly shown) is coupled to the fluid port 114. Such an arrangement allows a relative vacuum to be applied to the wound via the fluid conductor 108. In addition, a source of ultra-violet light (not explicitly shown) is coupled to the fiber-optic strands 118. The ultra-violet light is emitted from the fiber-optic strands 118 into the wound. The ultraviolet light emitted from the fiber-optic strands 118 may be modulated to create various patterns of light, different intensities of light, and different durations of light such as, for example, pulsed emission of ultraviolet light. The ultraviolet light is capable of penetrating through several layers of skin to destroy infectious bacteria. According to exemplary embodiments, the ultraviolet light from fiber-optic strands 118 destroys a wide variety of microorganisms such as, for example, bacteria which causes skin infections. In addition, the ultraviolet light from the fiber-optic strands 118 improves wound healing along with cell and bone growth. Furthermore, the use of ultraviolet light in light therapy is safe, non-invasive, drug-free and therapeutic.


Still referring to FIGS. 1C-2, in various embodiments, a therapeutic agent, such as, for example, concentrated oxygen may be applied to the wound site via the port 114. In such embodiments, the port 114 may include two parallel lumen couplings to facilitate alternating application of the therapeutic agent and the relative vacuum. In various embodiments, the therapeutic agent may be thermally augmented prior to application to the wound area. In other embodiments, the therapeutic agent is not thermally augmented. Still referring to FIGS. 1C-2, in various embodiments, a radio frequency (“RF”) antenna 122 is disposed around the window 120. In a typical embodiment, the RF antenna 122 comprises a wire 124. The wire 124 extends around a perimeter of the window 120. In a typical embodiment, the wire 124 is disposed such that, during use, the wire 124 is in close proximity to the wound. In various embodiments, the wire 124 is insulated to reduce risk of electric shock to a patient.


Still referring to FIGS. 1C-2, during operation, a pulsed radio-frequency (“RF”) signal having a pulse frequency on the order of, for example 27 MHz, is transmitted to the RF antenna 122. In a typical embodiment, an amplitude of the pulsed RF signal is on the order of, for example, a fraction of a Watt. Such an amplitude is below a threshold where federal licensing is typically required. The RF antenna 122 receives the pulsed RF signal from a radio-frequency source and transmits the pulsed RF signal to a region in close proximity to the wound. Exposing the wound to the pulsed RF signal has been shown to be beneficial to healing by encouraging intracellular communication. In particular, pulsed RF signals have been shown to stimulate cellular bonding, and metabolism.



FIG. 3 is a flow diagram of a process 300 for using the wound-care patch 100. The process 300 begins at step 302. At step 304, the wound-care patch 100 is applied to a wound. At step 306, a biocompatible skin adhesive is used to secure the edges of the wound care patch 100 to a patient's skin surrounding the wound. At step 308, the fluid port 114 is coupled to a vacuum source and the fiber-optic cable 116 is connected to an ultraviolet light source. At step 310, a relative vacuum is applied to the fluid port 114. The relative vacuum is transmitted to the wound via the fluid conductor 108. In various embodiments, the relative vacuum facilitates removal of undesirable tissues from the wound such as, for example, dead tissue and foreign contaminants. In addition, the relative vacuum draws out fluid from the wound thereby increasing blood flow into the wound area. At step 312, ultraviolet light is supplied to the wound via the fiber-optic cable 116 and the fiber-optic strands 118. In a typical embodiment, the ultraviolet light is supplied to the wound area simultaneous with the application of the relative vacuum. In other embodiments, at least one of the ultraviolet light and the relative vacuum may be modulated or applied in various patterns and, thus, may not be simultaneous. The process 300 ends at step 314.



FIG. 4A is a top view of a package 401 containing a wound-care assembly 400. FIG. 4B is an exploded view of the wound-care assembly 400. Referring to FIGS. 4A and 4B together, the wound-care assembly 400 includes a fiber-optic patch 402. The fiber-optic patch includes a plurality of fiber-optic strands 404. In a typical embodiment, the plurality of fiber-optic strands 404 are arranged in a generally flat side-by-side arrangement. The plurality of fiber-optic strands 404 are optically coupled to a fiber-optic cable 406. In a typical embodiment, the fiber-optic cable 406 is optically connectable to a source of ultraviolet light. The wound-care assembly 400 further includes a vacuum applicator 408. The vacuum applicator 408 includes a base layer 412 and a film layer 414. A fluid port 410 is formed in the film layer 414. A fluid conductor 416 is disposed beneath the fluid port 410 between the film layer 414 and the base layer 412. In a typical embodiment, the fluid conductor 416 is flexible, absorptive, and constructed of, for example, medical grade foam. In a typical embodiment, the fluid port 410 is connectable to a vacuum source. In a typical embodiment, the package 401 maintains the wound-care assembly in a sterile environment until use.


Still referring to FIGS. 4A and 4B, an RF layer 403 is disposed above the fiber-optic patch 402. The RF layer 403 includes an antenna 405 embedded therein. In a typical embodiment, the antenna 405 forms a loop around the wound. During operation, a pulsed radio-frequency (“RF”) signal having a pulse frequency on the order of, for example 27 MHz, is transmitted to the antenna 405. In a typical embodiment, an amplitude of the pulsed RF signal is on the order of, for example, a fraction of a Watt. Such an amplitude is below a threshold where federal licensing is typically required. The antenna 405 receives the pulsed RF signal from a radio-frequency source and transmits the pulsed RF signal to a region in close proximity to the wound. Exposing the wound to the pulsed RF signal has been shown to be beneficial to healing by encouraging intracellular communication. In particular, pulsed RF signals have been shown to stimulate cellular bonding, and metabolism.



FIG. 5A is a bottom view of the wound-care assembly 400 applied to a foot 502 of a patient. FIG. 5B is a top view of the wound-care assembly 400 applied to a foot 502 of a patient. As illustrated in FIGS. 5A-5B a wound 504 is present on the foot 502. The wound 504 is illustrated by way of example in FIG. 5 as being present on the foot 502; however, in other embodiments, the wound 504 may be disposed on any bodily region of the patient. The fiber-optic patch 402 is positioned over the wound 504 in such a manner that the fiber-optic strands 404 extend across a width of the wound 504. A fluid conductor 506 is shaped to approximately match a shape of the wound 504. In a typical embodiment, the fluid conductor 506 is flexible, absorptive, and constructed of, for example, medical grade foam. The fluid conductor 506 may cut or otherwise shaped to approximately match a size and shape of the wound 504. The fluid conductor 506 is positioned above the fiber-optic patch 402 and pressed downwardly into the wound 504 thereby pressing the fiber-optic strands 404 into contact with an interior surface of the wound 504. In various embodiments, a straw portion 508 may be fluidly coupled to the fluid conductor 506. In a typical embodiment, the straw portion 508 is constructed from a material similar to that of the fluid conductor 506. The straw portion 508 allows a relative vacuum to be applied to the wound 504, via the vacuum applicator 408, when the fluid port 410 is disposed a location remote to the wound 504 such as, for example, on a top of the foot 502. Such an arrangement is advantageous in situations where the wound 504 is located in a space-confined area such as, for example, a bottom of the patient's foot 502. The fiber-optic patch 402, the fluid conductor 506, and the straw portion 508 are secured in place via a biocompatible skin adhesive such as, for example, tegaderm.


Still referring to FIGS. 5A-5B, a small hole is formed in the biocompatible skin adhesive at a location where the vacuum applicator 408 is to be applied. In various embodiments, the vacuum applicator 408 is applied above the fluid conductor 506; however, in other embodiments, the vacuum applicator 408 may be applied to the straw portion 508. The vacuum applicator 408 is secured via a biocompatible skin adhesive such as, for example, tegaderm. In a typical embodiment, the wound-care assembly 400 facilitates flexible and modular construction for use on a wide variety of bodily areas and wound types.



FIG. 6 is a flow diagram of a process 600 for using the wound-care patch 400. The process 600 starts at step 602. At step 604, the fiber-optic patch 402 is placed over the wound 504. At step 606, the fluid conductor 506 is sized to approximately match a size and shape of the wound 504. At step 608, the fluid conductor 506 is pressed into the wound 504 above the fiber-optic patch 402. The fluid conductor 506 presses the fiber-optic strands 404 into contact with an inner surface of the wound 504. At step 610, a straw portion 508 is constructed in fluid communication with the fluid conductor 506. At step 612, the fiber-optic patch 402, the fluid conductor 506, and the straw portion 508 are secured with a biocompatible skin adhesive such as, for example, tegaderm. At step 614, the vacuum applicator is applied to at least one of the straw portion 508 or the fluid conductor 506.


Still referring to FIG. 6, at step 616, the fiber-optic cable 406 is connected to a source of ultraviolet light and the vacuum applicator 408 is fluidly coupled to a vacuum source. At step 618, a relative vacuum is applied to the wound 504 via the vacuum applicator 408, the fluid conductor 506, and, in some embodiments, the straw portion 508. In various embodiments, the relative vacuum facilitates removal undesirable tissues from the wound 504. At step 620, ultraviolet light is applied to the wound 504 via the fiber-optic cable 406, the fiber-optic patch 402, and the fiber-optic strands 404. In a typical embodiment, the ultraviolet light is supplied to the wound 504 simultaneous with the application of the relative vacuum. In other embodiments, at least one of the ultraviolet light and the relative vacuum may be modulated or applied in various patterns and, thus, may not be simultaneous. The process 600 ends at step 622.


Although various embodiments of the method and system of the present invention have been illustrated in the accompanying Drawings and described in the foregoing Specification, it will be understood that the invention is not limited to the embodiments disclosed, but is capable of numerous rearrangements, modifications, and substitutions without departing from the spirit and scope of the invention as set forth herein. It is intended that the Specification and examples be considered as illustrative only.

Claims
  • 1. A wound-care assembly comprising: a base layer;a film layer operatively coupled to the base layer;a fluid conductor in fluid communication with a wound and a vacuum source, the fluid conductor being sized to fit inside the wound;a fiber-optic patch comprising a plurality of fiber-optic strands, the fiber-optic strands being pressed and secured into contact with an interior surface of the wound by the fluid conductor;wherein the fiber-optic patch provides ultraviolet light to the wound; andwherein a relative vacuum is applied to the wound via the vacuum source and the fluid conductor.
  • 2. The wound-care assembly of claim 1, further comprising a fluid port fluidly coupled to the fluid conductor.
  • 3. The wound-care assembly of claim 2, wherein the fluid conductor comprises a straw portion that facilitates placement of the fluid port at a location distal to the wound.
  • 4. The wound-care assembly of claim 2, wherein a therapeutic agent is applied to the wound via the fluid port.
  • 5. The wound-care assembly of claim 4, wherein the therapeutic agent is thermally augmented.
  • 6. The wound-care assembly of claim 1, wherein the fiber-optic strands are arranged in a flat, side-by-side, configuration.
  • 7. The wound-care assembly of claim 1, further comprising a window formed in the base layer, the window facilitating fluid communication between the wound and the fluid conductor.
  • 8. The wound-care assembly of claim 7, further comprising a mesh extending across the window.
  • 9. The wound-care assembly of claim 7, further comprising a radio-frequency (RF) antenna disposed around a circumference of the window.
  • 10. The wound-care assembly of claim 1, wherein the fluid conductor facilitates reduction of pressure at the wound from ambient pressure.
  • 11. A method of utilizing a wound-care assembly, the method comprising: applying a fiber-optic patch to a wound;sizing a fluid conductor to fit inside the wound;pressing and securing the fiber-optic patch into contact with an inner surface of the wound via the fluid conductor;applying a vacuum applicator to the fluid conductor;applying ultraviolet light to the wound via the fiber-optic patch; andapplying a relative vacuum to the wound via the fluid conductor.
  • 12. The method of claim 11, further comprising securing the fluid conductor and the fiber-optic patch to the wound.
  • 13. The method of claim 11, further comprising applying a therapeutic agent to the wound via the fluid conductor.
  • 14. The method of claim 13, further comprising thermally augmenting the therapeutic agent.
  • 15. The method of claim 11, further comprising applying a pulsed radio-frequency (RF) signal to the wound via a radio-frequency antenna.
  • 16. The method of claim 11, wherein applying ultraviolet light comprises modulating the applied ultraviolet light.
  • 17. The method of claim 11, wherein applying a relative vacuum comprises fluidly coupling the vacuum applicator to a straw portion of the fluid conductor at a location distal to the wound.
  • 18. The method of claim 11, further comprising shaping the fluid conductor to approximately match a size and a shape of the wound.
  • 19. The method of claim 11, wherein applying a relative vacuum to a wound facilitates removal of undesirable materials from the wound.
  • 20. The method of claim 11, wherein the fiber-optic patch comprises fiber-optic strands arranged in a flat side-by-side configuration.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to, and incorporates by reference for any purpose the entire disclosure of, U.S. Provisional Patent Application No. 61/902,455, filed Nov. 11, 2013.

US Referenced Citations (439)
Number Name Date Kind
773828 Titus Nov 1904 A
2110022 Kliesrath Mar 1938 A
2504308 Donkle, Jr. Apr 1950 A
3014117 Madding Dec 1961 A
3164152 Vere Nicoll Jan 1965 A
3345641 Jennings Oct 1967 A
3367319 Carter, Jr. Feb 1968 A
3548809 Conti Dec 1970 A
3608091 Olson et al. Sep 1971 A
3660849 Jonnes et al. May 1972 A
3736764 Chambers et al. Jun 1973 A
3738702 Jacobs Jun 1973 A
3744053 Parker et al. Jul 1973 A
3744555 Fletcher et al. Jul 1973 A
3862629 Rotta Jan 1975 A
3894213 Agarwala Jul 1975 A
4006604 Seff Feb 1977 A
4013069 Hasty Mar 1977 A
4029087 Dye et al. Jun 1977 A
4206751 Schneider Jun 1980 A
4224941 Stivala Sep 1980 A
4375217 Arkans Mar 1983 A
4402312 Villari et al. Sep 1983 A
4459468 Bailey Jul 1984 A
4459822 Pasternack Jul 1984 A
4471787 Bentall Sep 1984 A
4503484 Moxon Mar 1985 A
4547906 Nishida et al. Oct 1985 A
4590925 Dillon May 1986 A
4597384 Whitney Jul 1986 A
4608041 Nielsen Aug 1986 A
D285821 Kneisley Sep 1986 S
D288372 Adams Feb 1987 S
4660388 Greene, Jr. Apr 1987 A
4738249 Linman et al. Apr 1988 A
D295897 Thimm-Kelly May 1988 S
4741338 Miyamae May 1988 A
4821354 Little Apr 1989 A
4844072 French et al. Jul 1989 A
4884304 Elkins Dec 1989 A
4901200 Mazura Feb 1990 A
4911231 Horne et al. Mar 1990 A
4926881 Ichinomiya et al. May 1990 A
4962761 Golden Oct 1990 A
4969881 Viesturs Nov 1990 A
4979375 Nathans et al. Dec 1990 A
4989589 Pekanmaki et al. Feb 1991 A
4995698 Myers Feb 1991 A
4996970 Legare Mar 1991 A
5044364 Crowther Sep 1991 A
5051562 Bailey et al. Sep 1991 A
D320872 McCrane Oct 1991 S
5062414 Grim Nov 1991 A
5067040 Fallik Nov 1991 A
5080089 Mason et al. Jan 1992 A
5090409 Genis Feb 1992 A
5092271 Kleinsasser Mar 1992 A
5097829 Quisenberry Mar 1992 A
5106373 Augustine et al. Apr 1992 A
5112045 Mason et al. May 1992 A
5117812 McWhorter Jun 1992 A
5125238 Ragan et al. Jun 1992 A
5165127 Nicholson Nov 1992 A
5179941 Siemssen et al. Jan 1993 A
5184612 Augustine Feb 1993 A
5186698 Mason et al. Feb 1993 A
5230335 Johnson, Jr. et al. Jul 1993 A
5232020 Mason et al. Aug 1993 A
5241951 Mason et al. Sep 1993 A
5243706 Frim et al. Sep 1993 A
5263538 Amidieu et al. Nov 1993 A
5285347 Fox et al. Feb 1994 A
D345082 Wenzl Mar 1994 S
D345609 Mason et al. Mar 1994 S
D345802 Mason et al. Apr 1994 S
D345803 Mason et al. Apr 1994 S
5300101 Augustine et al. Apr 1994 A
5300102 Augustine et al. Apr 1994 A
5300103 Stempel et al. Apr 1994 A
5303716 Mason et al. Apr 1994 A
5315994 Guibert et al. May 1994 A
5316250 Mason et al. May 1994 A
D348106 Mason et al. Jun 1994 S
5323847 Koizumi et al. Jun 1994 A
5324319 Mason et al. Jun 1994 A
5324320 Augustine et al. Jun 1994 A
D348518 Mason et al. Jul 1994 S
5330519 Mason et al. Jul 1994 A
5336250 Augustine Aug 1994 A
5343579 Dickerhoff et al. Sep 1994 A
5350417 Augustine Sep 1994 A
D351472 Mason et al. Oct 1994 S
5352174 Mason et al. Oct 1994 A
5354117 Danielson et al. Oct 1994 A
D352781 Mason et al. Nov 1994 S
5360439 Dickerhoff et al. Nov 1994 A
5370178 Agonafer et al. Dec 1994 A
5371665 Quisenberry et al. Dec 1994 A
D354138 Kelly Jan 1995 S
D357747 Kelly Apr 1995 S
5402542 Viard Apr 1995 A
5405370 Irani Apr 1995 A
5405371 Augustine et al. Apr 1995 A
5407421 Goldsmith Apr 1995 A
D358216 Dye May 1995 S
5411494 Rodriguez May 1995 A
5411541 Bell et al. May 1995 A
5417720 Mason May 1995 A
5440450 Lau et al. Aug 1995 A
5449379 Hadtke Sep 1995 A
5466250 Johnson, Jr. et al. Nov 1995 A
5496262 Johnson, Jr. et al. Mar 1996 A
5496357 Jensen et al. Mar 1996 A
5505726 Meserol Apr 1996 A
5507792 Mason Apr 1996 A
5509894 Mason et al. Apr 1996 A
5514079 Dillon May 1996 A
5528485 Devilbiss et al. Jun 1996 A
5561981 Quisenberry et al. Oct 1996 A
5566062 Quisenberry et al. Oct 1996 A
D376013 Sandman et al. Nov 1996 S
5578022 Scherson et al. Nov 1996 A
5588954 Ribando et al. Dec 1996 A
5591200 Cone et al. Jan 1997 A
D380874 Caswell Jul 1997 S
5648716 Devilbiss et al. Jul 1997 A
D383546 Amis et al. Sep 1997 S
D383547 Mason et al. Sep 1997 S
D383848 Mason et al. Sep 1997 S
5662695 Mason et al. Sep 1997 A
5669872 Fox Sep 1997 A
5672152 Mason et al. Sep 1997 A
5675473 McDunn et al. Oct 1997 A
5682748 DeVilbiss et al. Nov 1997 A
5689957 DeVilbiss et al. Nov 1997 A
5690849 DeVilbiss et al. Nov 1997 A
5711029 Visco et al. Jan 1998 A
5711155 DeVilbiss et al. Jan 1998 A
D393073 Downing et al. Mar 1998 S
5731954 Cheon Mar 1998 A
5733321 Brink Mar 1998 A
D394707 Tsubooka May 1998 S
5755755 Panyard May 1998 A
5772618 Mason et al. Jun 1998 A
5782780 Mason et al. Jul 1998 A
5795312 Dye Aug 1998 A
5807294 Cawley et al. Sep 1998 A
5827208 Mason Oct 1998 A
5831824 McDunn et al. Nov 1998 A
D403779 Davis et al. Jan 1999 S
D404490 Tripolsky Jan 1999 S
D405884 Roper Feb 1999 S
5865841 Kolen et al. Feb 1999 A
5871526 Gibbs et al. Feb 1999 A
5890371 Rajasubramanian et al. Apr 1999 A
5901037 Hamilton et al. May 1999 A
5923533 Olson Jul 1999 A
5947914 Augustine Sep 1999 A
5980561 Kolen et al. Nov 1999 A
5989285 DeVilbiss et al. Nov 1999 A
6007559 Arkans Dec 1999 A
6055157 Bartilson Apr 2000 A
6058010 Schmidt et al. May 2000 A
6058712 Rajasubramanian et al. May 2000 A
6080120 Sandman et al. Jun 2000 A
D428153 Davis Jul 2000 S
D430288 Mason et al. Aug 2000 S
D430289 Mason et al. Aug 2000 S
6117164 Gildersleeve et al. Sep 2000 A
6125036 Kang et al. Sep 2000 A
6129688 Arkans Oct 2000 A
6135116 Vogel et al. Oct 2000 A
6176869 Mason et al. Jan 2001 B1
6186977 Andrews et al. Feb 2001 B1
6231532 Watson et al. May 2001 B1
6235049 Nazerian May 2001 B1
6238427 Matta May 2001 B1
6260890 Mason Jul 2001 B1
6270481 Mason et al. Aug 2001 B1
6295819 Mathiprakasam et al. Oct 2001 B1
6305180 Miller et al. Oct 2001 B1
6319114 Nair et al. Nov 2001 B1
6352550 Gildersleeve et al. Mar 2002 B1
6358219 Arkans Mar 2002 B1
6368592 Colton et al. Apr 2002 B1
6436064 Kloecker Aug 2002 B1
6443978 Zharov Sep 2002 B1
6462949 Parish, IV et al. Oct 2002 B1
6468237 Lina Oct 2002 B1
6508831 Kushnir Jan 2003 B1
D472322 Hoglund et al. Mar 2003 S
D473315 Miros et al. Apr 2003 S
D473656 Miros et al. Apr 2003 S
D473948 Elkins et al. Apr 2003 S
6551264 Cawley et al. Apr 2003 B1
D474544 Hoglund et al. May 2003 S
6562060 Momtaheni May 2003 B1
6596016 Vreman Jul 2003 B1
6648904 Altshuler et al. Nov 2003 B2
D484601 Griffiths et al. Dec 2003 S
D484602 Griffiths et al. Dec 2003 S
6660027 Gruszecki et al. Dec 2003 B2
6667883 Solis et al. Dec 2003 B1
6675072 Kerem Jan 2004 B1
D486870 Mason Feb 2004 S
6695823 Lina et al. Feb 2004 B1
6719713 Mason Apr 2004 B2
6719728 Mason et al. Apr 2004 B2
6736787 McEwen et al. May 2004 B1
D492411 Bierman Jun 2004 S
6775137 Chu et al. Aug 2004 B2
D496108 Machin et al. Sep 2004 S
6789024 Kochan, Jr. et al. Sep 2004 B1
6802823 Mason Oct 2004 B2
D499846 Cesko Dec 2004 S
6834712 Parish et al. Dec 2004 B2
6846295 Ben-Nun Jan 2005 B1
6848498 Seki et al. Feb 2005 B2
6855158 Stolpmann Feb 2005 B2
6893414 Goble et al. May 2005 B2
D506553 Tesluk Jun 2005 S
6935409 Parish, IV et al. Aug 2005 B1
6936019 Mason Aug 2005 B2
D510140 Brown Sep 2005 S
6945988 Jones Sep 2005 B1
D510626 Krahner et al. Oct 2005 S
D515218 McGuire et al. Feb 2006 S
D523147 Tesluk Jun 2006 S
7066949 Gammons et al. Jun 2006 B2
7081128 Hart et al. Jul 2006 B2
D533668 Brown Dec 2006 S
D551351 Silva Sep 2007 S
D551352 Frangi Sep 2007 S
7306568 Diana Dec 2007 B2
7354411 Perry et al. Apr 2008 B2
D568482 Gramza et al. May 2008 S
D569985 Ganapathy et al. May 2008 S
7427153 Jacobs et al. Sep 2008 B1
7429252 Sarangapani Sep 2008 B2
7484552 Pfahnl Feb 2009 B2
7492252 Maruyama Feb 2009 B2
D595620 Kingsbury Jul 2009 S
D601707 Chouiller Oct 2009 S
D608006 Avitable et al. Jan 2010 S
D612947 Turtzo et al. Mar 2010 S
D613870 Shust Apr 2010 S
7717869 Eischen, Sr. May 2010 B2
D618358 Avitable et al. Jun 2010 S
D619267 Beckwith et al. Jul 2010 S
D620122 Cotton Jul 2010 S
7804686 Parish et al. Sep 2010 B2
D625018 Smith et al. Oct 2010 S
D626241 Sagnip et al. Oct 2010 S
D626242 Sagnip et al. Oct 2010 S
D626243 Sagnip et al. Oct 2010 S
D626245 Sagnip et al. Oct 2010 S
D627896 Matsuo et al. Nov 2010 S
D628300 Caden Nov 2010 S
D630759 Matsuo et al. Jan 2011 S
7871387 Tordella et al. Jan 2011 B2
D631971 Turtzo et al. Feb 2011 S
D633657 Oban Mar 2011 S
D634437 Gramza et al. Mar 2011 S
D634851 Chiang Mar 2011 S
D635266 Chiang Mar 2011 S
D635267 Chiang Mar 2011 S
7896910 Schirrmacher et al. Mar 2011 B2
7909861 Balachandran et al. Mar 2011 B2
D636497 Giaccone Apr 2011 S
D638950 Janzon May 2011 S
D640380 Tweardy et al. Jun 2011 S
D640381 Tweardy et al. Jun 2011 S
7959588 Wolpa Jun 2011 B1
8007491 Pinto et al. Aug 2011 B2
D649648 Cavalieri et al. Nov 2011 S
8052630 Kloecker et al. Nov 2011 B2
8088113 Scherson et al. Jan 2012 B2
8100956 Quisenberry et al. Jan 2012 B2
8109981 Gertner et al. Feb 2012 B2
D655420 Bowles Mar 2012 S
D655821 Matsuo Mar 2012 S
8128672 Quisenberry et al. Mar 2012 B2
8142486 Quisenberry et al. Mar 2012 B2
D657063 Chiang Apr 2012 S
8157792 Dolliver et al. Apr 2012 B2
D660438 Kennedy et al. May 2012 S
D660439 Chen et al. May 2012 S
D662212 Quisenberry Jun 2012 S
D662213 Quisenberry Jun 2012 S
D662214 Quisenberry Jun 2012 S
D663850 Joseph Jul 2012 S
D664260 Quisenberry Jul 2012 S
D665088 Joseph Aug 2012 S
D665470 Galbraith Aug 2012 S
D666258 Campbell Aug 2012 S
D666301 Joseph Aug 2012 S
8248798 Parish et al. Aug 2012 B2
D679023 Quisenberry Mar 2013 S
8425580 Quisenberry et al. Apr 2013 B2
D683042 Quisenberry et al. May 2013 S
8444581 Maxon-Maldonado et al. May 2013 B1
8449483 Eddy May 2013 B2
8485995 Maxon-Maldonado Jul 2013 B1
8569566 Blott et al. Oct 2013 B2
8574278 Quisenberry Nov 2013 B2
8632576 Quisenberry et al. Jan 2014 B2
8753300 Deshpande Jun 2014 B2
8753383 Parish et al. Jun 2014 B2
8758419 Quisenberry et al. Jun 2014 B1
8778005 Parish et al. Jul 2014 B2
8827935 Maxon-Maldonado Sep 2014 B2
8834393 Maxon-Maldonado et al. Sep 2014 B2
8940034 Quisenberry Jan 2015 B2
9101463 Stormby Aug 2015 B2
9119705 Parish et al. Sep 2015 B2
9180041 Parish et al. Nov 2015 B2
9192539 Parish et al. Nov 2015 B2
20010018604 Elkins Aug 2001 A1
20010039439 Elkins et al. Nov 2001 A1
20020116041 Daoud Aug 2002 A1
20020143373 Courtnage et al. Oct 2002 A1
20030050594 Zamierowski Mar 2003 A1
20030083610 McGrath et al. May 2003 A1
20030089486 Parish et al. May 2003 A1
20030089487 Parish, IV et al. May 2003 A1
20030127215 Parish, IV et al. Jul 2003 A1
20030135252 MacHold et al. Jul 2003 A1
20030163183 Carson Aug 2003 A1
20030171703 Grim et al. Sep 2003 A1
20030176822 Morgenlander Sep 2003 A1
20030191437 Knighton et al. Oct 2003 A1
20040008483 Cheon Jan 2004 A1
20040030281 Goble et al. Feb 2004 A1
20040046108 Spector Mar 2004 A1
20040054307 Mason et al. Mar 2004 A1
20040068309 Edelman Apr 2004 A1
20040068310 Edelman Apr 2004 A1
20040099407 Parish, IV et al. May 2004 A1
20040133135 Diana Jul 2004 A1
20040176805 Whelan et al. Sep 2004 A1
20040186535 Knowlton Sep 2004 A1
20040193218 Butler Sep 2004 A1
20040210176 Diana Oct 2004 A1
20040221604 Ota et al. Nov 2004 A1
20040260231 Goble et al. Dec 2004 A1
20050004636 Noda et al. Jan 2005 A1
20050006061 Quisenberry et al. Jan 2005 A1
20050033390 McConnell Feb 2005 A1
20050039887 Parish, IV et al. Feb 2005 A1
20050070828 Hampson et al. Mar 2005 A1
20050070835 Joshi Mar 2005 A1
20050080465 Zelickson et al. Apr 2005 A1
20050133214 Pfahnl Jun 2005 A1
20050143797 Parish et al. Jun 2005 A1
20050177093 Barry Aug 2005 A1
20050182364 Burchman Aug 2005 A1
20050187500 Perry et al. Aug 2005 A1
20050256556 Schirrmacher et al. Nov 2005 A1
20050274120 Quisenberry et al. Dec 2005 A1
20050284615 Parish et al. Dec 2005 A1
20060034053 Parish et al. Feb 2006 A1
20060058714 Rhoades Mar 2006 A1
20060116620 Oyaski Jun 2006 A1
20060167531 Gertner et al. Jul 2006 A1
20060217787 Olson Sep 2006 A1
20060241549 Sunnen Oct 2006 A1
20060253089 Lin Nov 2006 A1
20060276845 George et al. Dec 2006 A1
20060282028 Howard Dec 2006 A1
20070032778 Heaton et al. Feb 2007 A1
20070068651 Gammons et al. Mar 2007 A1
20070112401 Balachandran et al. May 2007 A1
20070118194 Mason et al. May 2007 A1
20070129658 Hampson et al. Jun 2007 A1
20070233209 Whitehurst Oct 2007 A1
20070260162 Meyer et al. Nov 2007 A1
20070282249 Quisenberry Dec 2007 A1
20080058911 Parish et al. Mar 2008 A1
20080064992 Stewart et al. Mar 2008 A1
20080071330 Quisenberry et al. Mar 2008 A1
20080082029 Diana Apr 2008 A1
20080103397 Barak May 2008 A1
20080103422 Perry et al. May 2008 A1
20080125775 Morris May 2008 A1
20080132816 Kane et al. Jun 2008 A1
20080132976 Kane et al. Jun 2008 A1
20080249559 Brown et al. Oct 2008 A1
20080262399 Kovelman et al. Oct 2008 A1
20080319362 Joseph Dec 2008 A1
20090069731 Parish et al. Mar 2009 A1
20090109622 Parish et al. Apr 2009 A1
20090149821 Scherson et al. Jun 2009 A1
20090237264 Bobey Sep 2009 A1
20090254159 Stormby Oct 2009 A1
20090254160 Shawver et al. Oct 2009 A1
20100010477 Augustine et al. Jan 2010 A1
20100030306 Edelman et al. Feb 2010 A1
20100081975 Avitable et al. Apr 2010 A1
20100121230 Vogel et al. May 2010 A1
20100137764 Eddy Jun 2010 A1
20100145421 Tomlinson et al. Jun 2010 A1
20100150991 Bernstein Jun 2010 A1
20100160838 Krespi Jun 2010 A1
20100179469 Hammond Jul 2010 A1
20100186436 Stormby Jul 2010 A1
20100210982 Balachandran et al. Aug 2010 A1
20100249679 Perry et al. Sep 2010 A1
20100249680 Davis Sep 2010 A1
20110009785 Meyer et al. Jan 2011 A1
20110034861 Schaefer Feb 2011 A1
20110037002 Johnson et al. Feb 2011 A1
20110071447 Liu et al. Mar 2011 A1
20110082401 Iker et al. Apr 2011 A1
20110087142 Ravikumar et al. Apr 2011 A1
20110275983 Quisenberry et al. Nov 2011 A1
20110282269 Quisenberry et al. Nov 2011 A1
20120041526 Stormby Feb 2012 A1
20120259266 Quisenberry Oct 2012 A1
20120289885 Cottrell Nov 2012 A1
20130030331 Quisenberry et al. Jan 2013 A1
20130103123 Khan Apr 2013 A1
20130116612 Stephan May 2013 A1
20130216627 Galbraith et al. Aug 2013 A1
20130245508 Maxon-Maldonado Sep 2013 A1
20130245519 Edelman et al. Sep 2013 A1
20130253383 Maxon-Maldonado Sep 2013 A1
20130261512 Maxon-Maldonado et al. Oct 2013 A1
20130281947 Quisenberry Oct 2013 A1
20140012169 Wilford et al. Jan 2014 A1
20140052054 Quisenberry Feb 2014 A1
20140257175 Quisenberry Sep 2014 A1
20140316330 Fudem et al. Oct 2014 A1
20140323949 Quisenberry Oct 2014 A1
20150133849 Quisenberry et al. May 2015 A1
20150290364 Wall et al. Oct 2015 A1
20150328042 Parish et al. Nov 2015 A1
20160030236 Parish et al. Feb 2016 A1
20160067104 Sarangapani et al. Mar 2016 A1
20160082238 Wells et al. Mar 2016 A1
Foreign Referenced Citations (17)
Number Date Country
670 541 Jun 1989 CH
35 22 127 Jan 1987 DE
0076074 Apr 1983 EP
0 489 326 Jun 1992 EP
2373444 Sep 2002 GB
689674 Oct 1979 SU
WO-9309727 May 1993 WO
WO-9312708 Jul 1993 WO
WO-9605873 Feb 1996 WO
WO-9807397 Feb 1998 WO
WO-0040186 Jul 2000 WO
WO-0114012 Mar 2001 WO
WO-0154635 Aug 2001 WO
WO-2004105676 Dec 2004 WO
WO-2005046760 May 2005 WO
WO-2010124234 Oct 2010 WO
WO-2012067918 May 2012 WO
Non-Patent Literature Citations (27)
Entry
U.S. Appl. No. 12/730,060, Parish et al.
U.S. Appl. No. 12/708,422, Balachandran et al.
U.S. Appl. No. 12/871,188, Parish et al.
U.S. Appl. No. 13/107,264, Quisenberry.
U.S. Appl. No. 12/364,434, Quisenberry.
U.S. Appl. No. 13/190,564, Quisenberry et al.
U.S. Appl. No. 29/397,856, Quisenberry.
U.S. Appl. No. 29/400,194, Quisenberry.
U.S. Appl. No. 29/400,202, Quisenberry.
U.S. Appl. No. 29/400,212, Quisenberry.
U.S. Appl. No. 29/402,115, Quisenberry.
U.S. Appl. No. 13/796,139, Quisenberry.
U.S. Appl. No. 13/962,994, Quisenberry.
U.S. Appl. No. 14/062,428, Quisenberry.
U.S. Appl. No. 14/197,324, Quisenberry.
Artikis, T., PCT International Preliminary Report on Patentability as mailed Jul. 29, 2005, (10 pgs.).
Tom Lee, T.Y. et al; “Compact Liquid Cooling System for Small, Moveable Electronic Equipment”, IEEE Transactions on Components, Hybrids, and Manufacturing Technology, Oct. 15, 1992, vol. 15, No. 5, pp. 786-793.
Copenheaver, Blaine R., “International Search Report” for PCT/US2007/022148 as mailed Apr. 2, 2008, 2 pages.
Young, Lee W., “International Search Report” for PCT/US07/08807 as mailed Mar. 3, 2008, (3 pages).
Mahmoud Karimi Azar Daryany, et al., “Photoinactivation of Escherichia coli and Saccharomyces cerevisiae Suspended in Phosphate-Buffered Saline-A Using 266- and 355-nm Pulsed Ultraviolet Light”, Curr Microbiol, vol. 56, 2008, pp. 423-428.
J. Li, et al., “Enhanced germicidal effects of pulsed UV-LED irradiation on biofilms”, Journal of Applied Microbiology, 2010, pp. 1-8.
Cyro/Temp Therapy Systems; Product News Catalogue; Jobst Institute, Inc., 6 pages (Copyright 1982).
Copenheaver, Blaine R., “International Search Report” for PCT/US2012/035096 as mailed Aug. 7, 2012, 3 pages.
Copenheaver, Blaine R., “International Search Report” prepared for PCT/US2013/030475 as mailed May 23, 2013, 3 pages.
Young, Lee W., International Search Report of PCT Application No. PCT/US2014/64805, Mar. 13, 2015 (3 pages).
U.S. Appl. No. 15/227,417, filed Aug. 3, 2016, Overton et al.
U.S. Appl. No. 15/370,689, Quisenberry.
Related Publications (1)
Number Date Country
20150133849 A1 May 2015 US
Provisional Applications (1)
Number Date Country
61902455 Nov 2013 US